| Business Summary | | Valentis,
Inc.
is
engaged
in
the
field
of
biopharmaceutical
delivery.
The
Company
develops
multiple
proprietary
gene
delivery
and
gene
expression
systems
and
PEGylation
technologies
and
applies
its
preclinical
and
early
clinical
development
expertise
to
create
novel
therapeutics
and
improved
versions
of
currently
marketed
biopharmaceuticals.
Valentis
has
what
it
believes
to
be
the
broadest
array
of
technologies
and
intellectual
property
for
the
delivery
of
biopharmaceuticals
including
genes,
proteins,
peptides,
peptidomimetics,
antibodies
and
replicating
and
non-replicating
viruses.
Valentis
focuses
on
research,
preclinical
development
and
early-stage
clinical
development
of
products
in
several
therapeutic
areas
including
cardiovascular
disorders,
oncology,
hematology
and
immunology.
The
Company's
delivery
systems
for
biopharmaceuticals
are
based
on
two
broad
technology
platforms:
gene
medicines
and
PEGylation
technologies. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Valentis
develops
novel
therapeutics
using
its
proprietary
technologies,
including
multiple
gene
delivery
and
gene
expression
systems
and
PEGylation
technologies
designed
to
improve
the
safety,
efficacy
and
dosing
characteristics
of
genes,
proteins
and
viruses.
For
the
nine
months
ended
3/31/01,
revenues
fell
30%
to
$3.2
million.
Net
loss
applicable
to
Common
fell
22%
to
$29.1
million.
Results
reflect
lower
amounts
from
Roche,
offset
by
the
absence
of
R&D
charges. Recent Earnings Announcement For
the
3
months
ended
06/30/2001,
revenues
were
1,476;
after
tax
earnings
were
-10,415. (Preliminary; reported in thousands of dollars.) | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Benjamin McGraw III, 51 Chairman,
Pres, CEO | $356K | -- | Bennet Weintraub, 46 CFO
and VP, Fin. | 203K | -- | J. Tyler Martin, M.D., 41 VP,
Clinical Devel. and Regulatory Affairs | -- | -- | Margaret Snowden, 41 VP,
Intellectual Property and Legal Affairs | 151K | $37K | Alain Rolland, Ph.D., 40 VP-R&D | 217K | -- | Dollar amounts are as of 30-June-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|